Brain metastases from thyroid cancer (TC) are rare but signify an advanced stage of the disease with poor survival outcomes. This study aimed to identify prognostic factors associated with brain metastasis-specific survival (BMS) in patients with brain metastases from TC.
Methods:
A systematic review and meta-analysis were conducted. Data were extracted from studies retrieved from PubMed, Scopus, Embase, and MEDLINE up to July 18, 2025. A multivariable Cox proportional hazards model was used to estimate hazard ratios (HRs) for potential prognostic factors.
Results:
A total of 24 studies, including 301 patients with brain metastases from TC, were included. BMS was 18 months (confidence interval [CI], 1.07 to 3.56). Key prognostic factors associated with decreased BMS included anaplastic thyroid carcinoma (HR, 3.3; CI, 1.06 to 10.3; p = 0.04), poorly differentiated thyroid carcinoma (HR, 1.95; CI, 1.07 to 3.56; p = 0.03), poor performance status (Eastern Cooperative Oncology Group >1) (HR, 2.62; CI, 1.69 to 4.05; p < 0.001), multiple brain metastases (HR, 1.89; CI, 1.24 to 2.89; p = 0.004), and the presence of distant metastases (HR, 1.97; CI, 1.13 to 3.44; p = 0.018). Neither the size nor the anatomical location of brain metastases was significantly associated with BMS.
Conclusions:
Brain metastases from TC are associated with poor survival, with key prognostic factors including aggressive tumor subtypes, poor performance status, multiple brain metastases, and the presence of extracranial metastases, particularly in the lungs. These findings highlight the need for a multidisciplinary approach and the importance of systemic disease control in improving outcomes for this challenging patient population.
SchlumbergerMJ. Papillary and follicular thyroid carcinoma. N Engl J Med, 1998; 338(5):297–306; doi: 10.1056/NEJM199801293380506
2.
WolffL, SteindlA, PopovP, et al.Clinical characteristics, treatment, and long-term outcome of patients with brain metastases from thyroid cancer. Clin Exp Metastasis, 2023; 40(3):217–226; doi: 10.1007/s10585-023-10208-8
3.
AbeI, LamAK-Y. Anaplastic thyroid carcinoma: Updates on WHO classification, clinicopathological features and staging. Histol Histopathol, 2021; 36(3):239–248; doi: 10.14670/HH-18-277
4.
ChiuAC, DelpassandES, ShermanSI. Prognosis and treatment of brain metastases in thyroid carcinoma. J Clin Endocrinol Metab, 1997; 82(11):3637–3642; doi: 10.1210/jcem.82.11.4386
5.
GasparL, ScottC, RotmanM, et al.Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys, 1997; 37(4):745–751; doi: 10.1016/s0360-3016(96)00619-0
6.
SperdutoPW, BerkeyB, GasparLE, et al.A new prognostic index and comparison to three other indices for patients with brain metastases: An analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys, 2008; 70(2):510–514; doi: 10.1016/j.ijrobp.2007.06.074
7.
SperdutoPW, KasedN, RobergeD, et al.Summary report on the graded prognostic assessment: An accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol, 2012; 30(4):419–425; doi: 10.1200/JCO.2011.38.0527
8.
SperdutoPW, JiangW, BrownPD, et al.Estimating survival in melanoma patients with brain metastases: An update of the graded prognostic assessment for melanoma using molecular markers (Melanoma-molGPA). Int J Radiat Oncol Biol Phys, 2017; 99(4):812–816; doi: 10.1016/j.ijrobp.2017.06.2454
9.
SperdutoPW, KasedN, RobergeD, et al.The effect of tumor subtype on survival and the Graded Prognostic Assessment (GPA) for patients with breast cancer and brain metastases. Int J Radiat Oncol Biol Phys, 2012; 82(5):2111–2117; doi: 10.1016/j.ijrobp.2011.02.027
10.
PageMJ, McKenzieJE, BossuytPM, et al.The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Syst Rev, 2021; 10(1):89; doi: 10.1186/s13643-021-01626-4
11.
OuzzaniM, HammadyH, FedorowiczZ, et al.Rayyan-a web and mobile app for systematic reviews. Syst Rev, 2016; 5(1):210; doi: 10.1186/s13643-016-0384-4
12.
BuneviciusA, FribanceS, PikisS, et al.Stereotactic radiosurgery for differentiated thyroid cancer brain metastases: An international, multicenter study. Thyroid, 2021; 31(8):1244–1252; doi: 10.1089/thy.2020.0947
13.
ChoiJ, KimJW, KeumYS, et al.the largest known survival analysis of patients with brain metastasis from thyroid cancer based on prognostic groups. PLoS One, 2016; 11(4):e0154739; doi: 10.1371/journal.pone.0154739
14.
BlomainE, BertaS, HugN, et al.Radiotherapy for brain metastases from thyroid cancer: An institutional and national retrospective cohort study. Thyroid, 2022; 32(7):781–788; doi: 10.1089/thy.2021.0628
15.
BernadDM, SperdutoPW, SouhamiL, et al.Stereotactic radiosurgery in the management of brain metastases from primary thyroid cancers. J Neurooncol, 2010; 98(2):249–252; doi: 10.1007/s11060-010-0175-z
16.
HarriesV, EaganA, TuttleRM, et al.The surgical management of intracranial metastasis secondary to follicular cell-derived thyroid carcinoma. J Surg Oncol, 2025; 131(2):316–324; doi: 10.1002/jso.27883
17.
ByunJ, SongSW, KimY-H, et al.Treatment outcome of gamma knife radiosurgery for brain metastasis from thyroid cancer: Favorable local control but poor survival. World Neurosurg, 2023; 171:e605–e610; doi: 10.1016/j.wneu.2022.12.070
18.
OsborneJR, KondraciukJD, RiceSL, et al.Thyroid Cancer brain metastasis: Survival and genomic characteristics of a large tertiary care cohort. Clin Nucl Med, 2019; 44(7):544–549; doi: 10.1097/RLU.0000000000002618
19.
AzamF, LatifMF, FarooqA, et al.Performance status assessment by using ECOG (Eastern Cooperative Oncology Group) Score for cancer patients by oncology healthcare professionals. Case Rep Oncol, 2019; 12(3):728–736; doi: 10.1159/000503095
20.
GubbiottiMA, LivolsiV. Brain metastases of papillary thyroid carcinoma origin are derived from aggressive histologic variants and demonstrate similar adverse morphology in the metastatic lesion. Clin Neurol Neurosurg, 2023; 227:107639; doi: 10.1016/j.clineuro.2023.107639
21.
Kleinschmidt-DeMastersB, MarshallC. Thyroid carcinoma metastases to central nervous system and vertebrae. Folia Neuropathol, 2022; 60(3):292–300; doi: 10.5114/fn.2022.118608
22.
WuSS, LamarreED, ScharpfJ, et al.Survival outcomes of advanced thyroid cancer enriched in brain metastases following treatment with small molecule inhibitors. Endocr Pract, 2023; 29(11):881–889; doi: 10.1016/j.eprac.2023.08.003
23.
AminMB, GreeneFL, EdgeSB, et al.The eighth edition AJCC cancer staging manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin, 2017; 67(2):93–99; doi: 10.3322/caac.21388
24.
Alonso‐GordoaT. Multimodal approach to the treatment of patients with radioiodine refractory differentiated thyroid cancer and metastases to the central nervous system. Cancer Med, 2022; 11(S1):33–39; doi: 10.1002/cam4.4901
25.
CoutoJS, AlmeidaMFO, TrindadeVCG, et al.A cutoff thyroglobulin value suggestive of distant metastases in differentiated thyroid cancer patients. Braz J Med Biol Res, 2020; 53(11):e9781; doi: 10.1590/1414-431X20209781
26.
SperdutoPW, YangTJ, BealK, et al.Estimating survival in patients with lung cancer and brain metastases: An update of the graded prognostic assessment for lung cancer using molecular markers (Lung-molGPA). JAMA Oncol, 2017; 3(6):827–831; doi: 10.1001/jamaoncol.2016.3834
27.
BiswalBM, BalCS, SandhuMS, et al.Management of intracranial metastases of differentiated carcinoma of thyroid. J Neurooncol, 1994; 22(1):77–81; doi: 10.1007/BF01058357
28.
ChenM, ChenD, XuJ, et al.Management of solitary intracranial metastases of differentiated thyroid carcinoma: 11 Pathologically confirmed cases and systematic literature review. World Neurosurg, 2018; 111:e888–e894; doi: 10.1016/j.wneu.2017.12.172
29.
Gomes-LimaCJ, WuD, RaoSN, et al.Brain metastases from differentiated thyroid carcinoma: Prevalence, current therapies, and outcomes. J Endocr Soc, 2019; 3(2):359–371; doi: 10.1210/js.2018-00241
30.
HaLN, KhanhLQ, HanhNTM, et al.Screening and treatment of brain metastasis from papillary thyroid carcinoma: A case series. Thyroid Res, 2023; 16(1):1; doi: 10.1186/s13044-023-00146-8
31.
Henriques de FigueiredoB, GodbertY, SoubeyranI, et al.Brain metastases from thyroid carcinoma: A retrospective study of 21 patients. Thyroid, 2014; 24(2):270–276; doi: 10.1089/thy.2013.0061
32.
HjiyiannakisP, JefferiesS, HarmerCL. Brain metastases in patients with differentiated thyroid carcinoma. Clin Oncol (R Coll Radiol), 1996; 8(5):327–330; doi: 10.1016/S0936-6555(05)80722-8
33.
KimI-Y, KondziolkaD, NiranjanA, et al.Gamma knife radiosurgery for metastatic brain tumors from thyroid cancer. J Neurooncol, 2009; 93(3):355–359; doi: 10.1007/s11060-008-9783-2
34.
LeeHS, YooH, LeeSH, et al.Clinical characteristics and follow-up of intracranial metastases from thyroid cancer. Acta Neurochir (Wien), 2015; 157(12):2185–2194; doi: 10.1007/s00701-015-2611-5
35.
McWilliamsRR, GianniniC, HayID, et al.Management of brain metastases from thyroid carcinoma: A study of 16 pathologically confirmed cases over 25 years. Cancer, 2003; 98(2):356–362; doi: 10.1002/cncr.11488
36.
MisakiT, IwataM, KasagiK, et al.Brain metastasis from differentiated thyroid cancer in patients treated with radioiodine for bone and lung lesions. Ann Nucl Med, 2000; 14(2):111–114; doi: 10.1007/BF02988589
37.
SalvatiM, CervoniL, CelliP. Solitary brain metastases from thyroid carcinoma: Study of 6 cases. Tumori, 1995; 81(2):142–143; doi: 10.1177/030089169508100214
38.
SamuelAM, ShahDH. Brain metastases in well-differentiated carcinoma of the thyroid. Tumori, 1997; 83(2):608–610; doi: 10.1177/030089169708300226
39.
Simões-PereiraJ, MacedoD, BugalhoMJ. Clinical outcomes of a cohort of patients with central nervous system metastases from thyroid cancer. Endocr Connect, 2016; 5(6):82–88; doi: 10.1530/EC-16-0049
40.
Slutzky-ShragaI, GorshteinA, PopovitzerA, et al.Clinical characteristics and disease outcome of patients with non-medullary thyroid cancer and brain metastases. Oncol Lett, 2018; 15(1):672–676; doi: 10.3892/ol.2017.7325
41.
TahmasebiFC, FarmerP, PowellSZ, et al.Brain metastases from papillary thyroid carcinomas. Virchows Arch, 2013; 462(4):473–480; doi: 10.1007/s00428-013-1394-4
42.
TsudaK, TsurushimaH, TakanoS, et al.Brain metastasis from papillary thyroid carcinomas. Mol Clin Oncol, 2013; 1(5):817–819; doi: 10.3892/mco.2013.139
43.
WuT, JiaoZ, LiY, et al.Brain metastases from differentiated thyroid carcinoma: A retrospective study of 22 patients. Front Endocrinol (Lausanne), 2021; 12:730025; doi: 10.3389/fendo.2021.730025
44.
YooJ, KimHJ, KimSM, et al.Prognostic factors to predict the efficacy of surgical interventions against brain metastasis secondary to thyroid cancer. Eur Thyroid J, 2022; 11(5):e220087; doi: 10.1530/ETJ-22-0087
45.
ZhangR, LiW, WangH, et al.Incidence and gender difference of brain metastases in newly diagnosed follicular thyroid cancer patients. Eur Thyroid J, 2024; 13(6):e240093; doi: 10.1530/ETJ-24-0093
46.
SperdutoPW, MeskoS, LiJ, et al.Survival in patients with brain metastases: Summary report on the updated diagnosis-specific graded prognostic assessment and definition of the eligibility quotient. J Clin Oncol, 2020; 38(32):3773–3784; doi: 10.1200/JCO.20.01255
47.
WolfA, KvintS, ChachouaA, et al.Toward the complete control of brain metastases using surveillance screening and stereotactic radiosurgery. J Neurosurg, 2018; 128(1):23–31; doi: 10.3171/2016.10.JNS161036
48.
SaitoF, UrunoT, ShibuyaH, et al.Prognosis after brain metastasis from differentiated thyroid carcinoma. World J Surg, 2016; 40(3):574–581; doi: 10.1007/s00268-016-3405-5
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
